orserdu
stemline therapeutics b.v. - elacestrant - bryst neoplasmer - endokrine terapi - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.
suxamethonium chloride "aguettant" 10 mg/ml injektionsvæske, opløsning i fyldt injektionssprøjte
laboratoire aguettant - suxamethoniumchlorid (vandfrit) - injektionsvæske, opløsning i fyldt injektionssprøjte - 10 mg/ml
divigel 1 mg/dosis
orion corporation - estradiolhemihydrat - gel - 1 mg/dosis
divigel 0,5 mg/dosis
orion corporation - estradiolhemihydrat - gel - 0,5 mg/dosis
delidose 1 mg/dosis gel
paranova danmark a/s - estradiolhemihydrat - gel - 1 mg/dosis
estring 7,5 mikrog./24 timer vaginalindlæg
paranova danmark a/s - estradiol - vaginalindlæg - 7,5 mikrog./24 timer
indivina 5 mg + 1 mg tabletter
orion corporation - estradiolvalerat, medroxyprogesteronacetat - tabletter - 5 mg + 1 mg
indivina 5 mg + 2 mg tabletter
orion corporation - estradiolvalerat, medroxyprogesteronacetat - tabletter - 5 mg + 2 mg
divina tabletter
paranova danmark a/s - estradiolvalerat, medroxyprogesteronacetat - tabletter
ercostrol 1 mg/dosis gel
orion corporation - estradiolhemihydrat - gel - 1 mg/dosis